Related Experiment Video

Updated: Aug 24, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Optimal dosing of dobutamine for treating post-resuscitation left ventricular dysfunction

Alejandro Vasquez1, Karl B Kern, Ronald W Hilwig

  • 1Section of Cardiology, Department of Medicine, Sarver Heart Center, University of Arizona College of Medicine, 1501 N. Campbell Avenue, Tucson, AZ 85724, USA.

Resuscitation
|May 12, 2004
PubMed

Insights

The optimal dobutamine dose for post-cardiac arrest recovery is 5 mcg/kgmin. This dose effectively improves left ventricular function without increasing myocardial oxygen demand, enhancing survival after resuscitation.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Post-resuscitation left ventricular dysfunction significantly impairs survival after cardiac arrest.
  • Dobutamine is a potential therapeutic agent for myocardial stunning.
  • Previous studies suggest 10 mcg/kgmin improves cardiac function but increases heart rate.

Purpose of the Study:

  • To determine the optimal dobutamine dosage for treating post-resuscitation left ventricular dysfunction.
  • To evaluate the effects of different dobutamine doses on cardiac function and myocardial oxygen consumption.

Main Methods:

  • Twenty swine underwent 12.5 minutes of ventricular fibrillation cardiac arrest and resuscitation.
  • Four groups received dobutamine at doses of 0, 2, 5, and 7.5 mcg/kgmin.
  • Cardiac function was assessed using ventriculograms, pressures, and cardiac output for 6 hours post-resuscitation.

Main Results:

  • Left ventricular dysfunction was observed post-resuscitation, peaking at 4 hours.
  • Dobutamine at 5 and 7.5 mcg/kgmin significantly improved systolic and diastolic function.
  • Tachycardia occurred with all dobutamine doses, but only significantly increased myocardial oxygen consumption at 7.5 mcg/kgmin.

Conclusions:

  • Dobutamine at 5 mcg/kgmin is optimal for restoring cardiac function post-resuscitation.
  • This dose improves systolic and diastolic function without negatively impacting myocardial oxygen consumption.
Abstract

More Related Videos

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.